Skip to main content
PLOS One logoLink to PLOS One
. 2025 Nov 24;20(11):e0337286. doi: 10.1371/journal.pone.0337286

Associations of cardiovascular health and social determinants of health with the risks of all-cause and cause-specific mortality

Boxuan Pu 1,*, Zun Wang 2
Editor: Angela Mendes Freitas3
PMCID: PMC12643303  PMID: 41284714

Abstract

Background

While cardiovascular health (CVH) and social determinants of health (SDoH) are independently associated with mortality, their combined effects on mortality remain unclear. The study aimed to examine the mediating, interacting, and combined effects of CVH and SDoH on mortality risks.

Methods

We analyzed data from 20,096 adults in the National Health and Nutrition Examination Survey 2007–2018. CVH was assessed using the Life’s Essential 8 (LE8) score and categorized into low, moderate, or high. Cumulative unfavorable SDoH burden was assessed and divided into low and high burdens of unfavorable SDoH. Multivariate Cox regression models were used to analyze the combined associations of SDoH and CVH with mortality. Mediation analysis was used to analyze the mediating role of CVH between SDoH and mortality. Interaction effects were tested by adding interaction terms between CVH and SDoH in the Cox models.

Results

A high burden of unfavorable SDoH was associated with higher risks of all-cause, cardiovascular disease (CVD), and cancer mortality. CVH significantly mediated these associations, accounting for 16.70% for all-cause mortality, 22.22% for CVD mortality, and 17.70% for cancer mortality. A significant additive interaction between SDoH and CVH was observed for all-cause mortality. Compared with individuals exhibiting neither risk factor, those with both low CVH and a high burden of unfavorable SDoH had significantly elevated risks of all-cause (hazard ratio [HR]: 4.60; 95% confidence interval [95% CI]: 2.87–7.37), CVD (2.80; 1.10–7.10), and cancer mortality (6.10; 2.13–17.50).

Conclusions

The coexistence of low CVH and a high burden of unfavorable SDoH was associated with increased risks of all-cause, CVD, and cancer mortality. These findings have implications for integrating SDoH and CVH in clinical practice and public health strategies to improve survival.

Introduction

Growing evidence has highlighted the crucial role of social determinants of health (SDoH) in causing disparities in clinical outcomes and health equity [1]. The World Health Organization defines SDoH as “the conditions in which people are born, grow, live, work, and age, and the wider set of forces and systems shaping the condition of daily life” [2]. The U.S. Healthy People 2030 initiative identifies a thorough SDoH framework covering five key domains: economic stability, education access and quality, health care access and quality, neighborhood and built environment, and social community context [3,4]. Adverse SDoH have been associated with high burdens of cardiovascular risk factors and adverse outcomes, such as cardiovascular disease (CVD), cancer, and mortality [1,57]. Approximately 30–55% of health outcomes are attributable to SDoH, suggesting their role as primary drivers of preventable health disparities [8]. Thus, public health interventions tackling adverse SDoH are critical for reducing health disparities.

The cumulative burden of adverse SDoH is associated with a lower likelihood of achieving optimal cardiovascular health (CVH) [9]. thereby increasing risks of mortality and CVD. SDoH provide the daily context for CVH and influence the potential to optimize CVH, as well as the effectiveness of interventions aiming at improving it [10]. Therefore, it is plausible that the association between SDoH and mortality could be mediated by CVH. However, this relationship remains unknown. In 2010, the American Heart Association (AHA) first proposed Life’s Simple 7 to measure CVH using 7 key metrics: smoking, diet, physical activity, body mass index (BMI), blood pressure (BP), cholesterol, and fasting glucose [11]. The metric was updated in 2022 as Life’s Essential 8 (LE8), adding sleep and refining other domains [12]. High CVH has been demonstrated to be related to longer life expectancy and reduced premature mortality [13,14]. Several studies explored the combined effects of specific CVH components and specific SDoH domains on health outcomes [1517]. However, these studies mainly examined one or two specific domains of SDoH or lifestyle components of CVH, and did not fully examine the combined effects of overall SDoH and CVH. Despite existing knowledge on the independent relationship of CVH and SDoH with health outcomes and their interlinkages, it remains unclear whether there is a combined effect of CVH and SDoH on mortality risks and to what extent CVH mediates the SDoH-mortality association.

To address these knowledge gaps, we analyzed data from the 2007–2018 National Health and Nutrition Examination Survey (NHANES) to investigate whether CVH modifies the association between SDoH and mortality. Further, this study also aimed to evaluate the interaction or combined associations of SDoH and CVH with mortality risks in a large representative sample of U.S. adults.

Methods

Study participants

In a two-year cycle starting at 1999–2000, NHANES used a stratified, multistage probability design to collect cross-sectional health and nutrition data from a nationally representative sample of the noninstitutionalized U.S. civilian population. Participants underwent an in-home interview followed by a visit to a mobile screening facility for anthropometric measurements, physiological examinations, and laboratory testing. The National Center for Health Statistics (NCHS) Ethics Review Board approved the NHANES protocols (No.: #2005–06, #2011–17, #2018-01), and all participants provided informed consent. This study used data from 6 consecutive NHANES cycles spanning 2007–2018. We excluded participants aged <20 years (n = 25,072), pregnant individuals (n = 372), those without mortality data (n = 115), and individuals with missing data on any individual component for SDoH (n = 1,809) or CVH (n = 12,378). Finally, the current study included 20,096 participants (S1 Fig).

CVH assessment

CVH was assessed using the LE8 score, which includes 4 health behaviors (diet, physical activity, tobacco/nicotine exposure, and sleep) and 4 health factors (BMI, non-high-density lipoprotein [non-HDL] cholesterol, blood glucose, and BP) (S1 Table). Diet quality was calculated using the Healthy Eating Index-2015 based on 24-hour dietary recalls [18]. Self-reported questionnaires provided data on sleep duration, smoking status, and physical activity levels. Trained investigators measured BP, blood glucose, height, and weight. BMI was calculated as weight (kg)/ height (m2). Glycated hemoglobin was measured using high-performance liquid chromatography methods. Non-HDL cholesterol was calculated as total cholesterol minus HDL cholesterol. Each LE8 component is scored 0–100, and the total CVH score represents the unweighted average of all 8 metrics, ranging from 0–100, with higher scores indicating better CVH. The CVH was categorized into low (LE8 < 50), moderate (50 ≤ LE8 < 80), or high (LE8 ≥ 80) [12,13].

SDoH assessment

By the U.S. Healthy People 2030, this study identified 8 sub-items of SDoH across 5 domains: social and community context (marital status), neighborhood and built environment (home ownership), health care access and quality (health insurance coverage and type), education access and quality (education level), and economic stability (employment status, family poverty-income ratio, and food security) (S2 Table) [3]. Each item was dichotomized using conventional cutoff points as favorable (level 0) or unfavorable (level 1). The cumulative burden of unfavorable SDoH was calculated by summing unfavorable items. Participants were categorized into high burden (>2 unfavorable SDoH) or low burden (≤2 unfavorable SDoH) based on previous studies [19,20].

Covariates

Covariates were obtained via standardized questionnaires, including self-reported age, sex, race/ethnicity, cancer history, and CVD history. The categories of race/ethnicity included Mexican American, non-Hispanic Black, non-Hispanic White, and other races. CVD history was defined as a self-reported physician diagnosis of any of the following: congestive heart failure, coronary heart disease, angina, myocardial infarction, or stroke. Likewise, cancer history was defined as a self-reported physician diagnosis of cancer or malignancy.

Outcomes

Deaths were ascertained through linkage with the National Death Index records, with follow-up through December 31, 2019. Underlying causes of death were determined using codes from the International Classification of Diseases, 10th Revision. CVD mortality was defined as death due to heart diseases (I00 to I09, I11, I13, I20 to I51, I60 to 169), and cancer mortality was defined as death due to cancer (C00 toC97).

Statistical analyses

We used weighted mean (standard error [SE]) to present continuous variables, and counts (survey-weighted percentages) for categorical variables. To compare characteristics across different levels of SDoH or CVH, we used analysis of variance for continuous variables and the chi-square test for categorical variables. The relationship between SDoH and CVH was evaluated using linear regression analysis.

Multivariate Cox proportional hazards models were used to estimate risks of all-cause and cause-specific mortality in relation to SDoH or CVH. The models were adjusted for age, sex, race/ethnicity, CVD, and cancer history. Mediation analyses were conducted using the R package “mediation” to quantify the extent to which CVH mediates the association between SDoH and mortality, with the proportion of mediation quantified by comparing models with and without adjustment for CVH. Bootstrap resampling (1000 simulations) was used to estimate of the mediation effect and its 95% confidence interval (95% CIs). Additionally, model predictive performance was evaluated by calculating the concordance index (C-index), integrated discrimination improvement (IDI), and net reclassification index (NRI) for models with and without SDoH.

A stratified analysis was performed based on SDoH levels to examine the association between CVH and mortality within different SDoH subgroups. To assess interactions between SDoH and CVH, an interaction term was incorporated into the multivariate models. Additive interactions were assessed via relative excess risk (RERI), attributable proportion (AP), and synergy index (SI). Multiplicative interactions were tested using interaction terms in Cox models. For the combined analyses, participants were classified into six groups by combined CVH and SDoH levels, and mortality risks were compared across these categories, with high CVH and a low burden of unfavorable SDoH as reference.

Subgroup analyses were conducted to assess potential effect modifications by age (<65 vs. ≥ 65 years), sex (men vs. women), and race/ethnicity (White vs. non-White). To evaluate the robustness of the primary findings, three sensitivity analyses were performed: first, excluding participants who died within the first two years of follow-up to minimize reverse causality; second, excluding those with CVD or cancer at baseline; and third, further adjusting for additional covariates including drinking status, chronic kidney disease, and chronic obstructive pulmonary disease.

No missing data were observed for covariates. All analyses were conducted using R 4.2.2 while accounting for the complex survey design of the NHANES database, including sampling weights, clustering, and stratification, ensuring nationally representative estimates. Two-sided P values <0.05 considered statistically significant.

Results

Participant characteristics

Among 20,096 participants (weighted population: 146,521,183), the mean age (SE) was 47.83 (0.28) years, and 10,254 (51.38%) were women. Of these participants, 11,262 (57.26%) had a high burden of unfavorable SDoH. Compared to the low burden group, those with a high burden of unfavorable SDoH were younger, more likely to be women and non-White, and had higher prevalence of CVD and poor CVH, and have poor CVH. Additionally, 5,275 (22.51%) individuals had low CVH, and 1,623 (10.76%) had high CVH. Individuals with high CVH tended to be younger, more likely to be women and White, and had lower prevalences of both CVD and cancer than those with low CVH (Table 1). Participants excluded from the analysis were younger, more likely to be non-White, and had a lower proportion of participants with CVD or cancer (S3 Table).

Table 1. Baseline characteristics of participants.

Characteristics Total Unfavorable SDoH CVH
Low burden High burden P value Low Moderate High P value
Weighted N (weighted %) 146,521,183 (100.0) 62,628,270

(42.74)
83,892,914

(57.26)
32,979,500 (22.51) 97,782,843

(66.74)
15,758,841

(10.76)
No. of participants in sample 20096 8834 11262 5275 13189 1632
Age, years (SE) 47.83 (0.28) 49.51 (0.28) 45.59 (0.41) <0.001 52.89 (0.34) 47.50 (0.31) 39.32 (0.55) <0.001
Women, n (weighted %) 10254 (51.38) 4302 (49.94) 5952 (53.51) <0.001 2526 (47.90) 6718 (50.57) 1010 (63.71) <0.001
Race/ethnicity, n (weighted %) <0.001 <0.001
 Mexican 2863 (7.78) 760 (3.89) 2103 (3.74) 699 (7.79) 1989 (8.18) 175 (5.27)
 White 9098 (70.18) 4858 (80.34) 4240 (56.58) 2381 (68.58) 5870 (69.79) 847 (76.02)
 Black 4000 (9.84) 1392 (5.96) 2608 (15.02) 1364 (13.30) 2476 (9.52) 160 (4.53)
 Other 4135 (12.20) 1824 (9.81) 2311 (15.41) 831 (10.33) 2854 (12.52) 450 (14.18)
Medical history, n (weighted %)
 CVD history 2144 (8.21) 679 (6.30) 1465 (10.78) <0.001 969 (15.49) 1131 (6.69) 44 (2.45) <0.001
 Cancer history 1972 (10.40) 983 (11.57) 989 (8.84) <0.001 581 (11.71) 1300 (10.52) 91 (6.92) <0.001
SDoH, n (weighted %)
 Unemployed 7714 (31.26) 2177 (22.16) 5537 (43.43) <0.001 2727 (43.95) 4654 (29.03) 333 (18.48) <0.001
 Family income-to-poverty ratio<300% 12535 (48.78) 2232 (19.43) 10293 (88.09) <0.001 3934 (63.25) 7913 (46.48) 688 (32.72) <0.001
 Marginal or lower food security 6232 (23.13) 513 (4.67) 5719 (47.86) <0.001 2181 (33.92) 3778 (21.29) 273 (11.97) <0.001
 Not owning a home 7435 (30.70) 1102 (11.64) 6333 (56.23) <0.001 2165 (34.39) 4700 (29.71) 570 (29.14) 0.003
 Less than high school 4363 (13.85) 401 (3.41) 3962 (27.83) <0.001 1652 (23.07) 2607 (12.40) 104 (3.53) <0.001
 No regular health care access 3608 (16.67) 513 (6.45) 3095 (30.37) <0.001 867 (16.68) 2422 (16.66) 319 (16.75) 0.996
 No private health insurance 9283 (35.71) 1057 (10.53) 8226 (69.44) <0.001 3020 (48.01) 5837 (34.14) 426 (19.71) <0.001
 Not married or living with a partner 7938 (35.29) 1689 (18.49) 6249 (57.79) <0.001 2268 (38.38) 5042 (34.46) 628 (33.95) 0.006
AHA LE8 score, mean (SE)
 Total CVH score 61.03 (0.32) 63.61 (0.35) 57.58 (0.37) <0.001 41.24 (0.17) 63.82 (0.15) 85.15 (0.12) <0.001
 HEI-2015 diet score 39.01 (0.24) 40.77 (0.27) 36.65 (0.27) <0.001 33.57 (0.32) 39.32 (0.24) 48.42 (0.59) <0.001
 Physical activity score 46.36 (0.83) 53.10 (1.00) 37.34 (0.90) <0.001 11.59 (0.58) 50.28 (0.78) 94.83 (0.45) <0.001
 Tobacco/nicotine exposure score 72.13 (0.55) 79.12 (0.53) 62.77 (0.80) <0.001 47.11 (0.84) 76.77 (0.53) 95.74 (0.38) <0.001
 Sleep health score 70.04 (1.02) 73.32 (1.47) 65.65 (0.91) <0.001 47.44 (1.61) 73.68 (0.98) 94.77 (0.39) <0.001
 Body mass index score 60.32 (0.42) 61.17 (0.53) 59.19 (0.53) 0.007 38.64 (0.62) 62.76 (0.43) 90.59 (0.55) <0.001
 Blood lipid score 63.43 (0.38) 62.73 (0.45) 64.37 (0.44) 0.010 44.51 (0.61) 65.81 (0.41) 88.28 (0.67) <0.001
 Blood glucose score 79.61 (0.31) 80.68 (0.41) 78.19 (0.37) <0.001 63.29 (0.47) 82.41 (0.30) 96.46 (0.36) <0.001
 Blood pressure score 57.35 (0.27) 57.99 (0.33) 56.50 (0.37) 0.002 43.80 (0.51) 59.54 (0.27) 72.15 (0.26) <0.001

Data are survey-weighted mean (SE) or N (weight percentage %).

Abbreviations: SE: standard error; CVD: cardiovascular diseases; SDoH: social determinants of health; CVH: cardiovascular health; AHA: American Heart Association; LE8: Life’s Essential 8; HEI-2015: healthy eating index-2015.

Mediation of CVH on SDoH-mortality association

During a median follow-up of 6.8 years (interquartile range: 4.0–9.9), 1,774 participants (6.29%) died from all causes, including 518 (1.75%) from CVD and 451 (1.65%) from cancer. After multivariable adjustment, individuals with a high burden of unfavorable SDoH had higher risks of all-cause (hazard ratio [HR], 2.32; 95% CI: 2.04–2.63), CVD (HR, 2.21; 95% CI: 1.75–2.80), and cancer mortality (HR, 1.72; 95% CI: 1.34–2.22) compared to the low-burden group. Similarly, individuals in the low CVH group had higher risks of all-cause (HR, 2.72; 95% CI: 1.85–3.99), CVD (HR, 2.84; 95% CI: 1.15–6.97), and cancer mortality (HR, 2.56; 95% CI: 1.21–5.43) compared to those in the high CVH group (Table 2). Furthermore, each unit increase in unfavorable SDoH correlated with significantly lower CVH scores (β = −1.91; 95% CI: −2.00- −1.81, P < 0.001) (S4 Table).

Table 2. Independent association of social determinants of health and cardiovascular health with all-cause and cause-specific mortality.

Outcomes Death/No. Weighted death (%) Adjusted HR (95% CI) Adjusted P value
All-cause mortality
Unfavorable SDoH
 Low burden 554/8834 3,654,817 (4.36) 1 (Reference)
 High burden 1220/11262 5,561,140 (8.88) 2.32 (2.04-2.63) <0.001
 Per 1 unfavorable SDoH increase 1.32 (1.28-1.37) <0.001
CVH
 High 40/1632 256,500 (1.63) 1 (Reference)
 Moderate 971/13189 5,033,088 (5.15) 1.53 (1.06-2.20) 0.022
 Low 763/5275 3,926,370 (11.91) 2.72 (1.85-3.99) <0.001
 Per 10 CVH scores decrease 1.32 (1.23-1.39) <0.001
CVD mortality
Unfavorable SDoH
 Low burden 158/8834 983,648 (1.17) 1 (Reference)
 High burden 360/11262 1,584,263 (2.53) 2.21 (1.75-2.80) <0.001
 Per 1 unfavorable SDoH increase 1.30 (1.22-1.39) <0.001
CVH
 High 8/1632 57,143 (0.36) 1 (Reference)
 Moderate 287/13189 1,400,529 (1.43) 1.65 (0.67-4.04) 0.300
 Low 223/5275 1,110,239 (3.37) 2.84 (1.15-6.97) 0.023
 Per 10 CVH scores decrease 1.37 (1.23-1.51) <0.001
Cancer mortality
Unfavorable SDoH
 Low burden 170/8834 1,180,251 (1.41) 1 (Reference)
 High burden 281/11262 1,248,140 (1.99) 1.72 (1.34-2.22) <0.001
 Per 1 unfavorable SDoH increase 1.18 (1.09-1.28) <0.001
CVH
 High 11/1632 69,072 (0.44) 1 (Reference)
 Moderate 259/13189 1,447,269 (1.48) 1.66 (0.79-3.52) 0.200
 Low 181/5275 912,050 (2.77) 2.56 (1.21-5.43) 0.014
 Per 10 CVH scores decrease 1.20 (1.09-1.33) <0.001

Multivariate models were adjusted for age, sex, race/ethnicity, cardiovascular disease history, and cancer history.

Abbreviations: SDoH: social determinants of health; CVH: cardiovascular health; HR: hazard ratio; CI: confidence interval; CVD: cardiovascular diseases.

When additionally adjusting for CVH, the HRs for the association between SDoH and all-cause, CVD, and cancer mortality were attenuated but still significant compared with models without CVH adjustment. Mediation analyses further showed that CVH significantly mediated the association between SDoH and all-cause mortality (mediation proportion: 16.70%; 95% CI: 10.90–18.96), CVD mortality (22.22%; 95% CI: 8.63–27.98), and cancer mortality (17.70%; 95% CI: 9.48–42.79) (Table 3, S2 Fig). Furthermore, incorporating SDoH significantly improved mortality risk prediction across all outcomes, with increased C-index, NRI, and IDI improvements (S5 Table).

Table 3. Mediation of cardiovascular health on the associations between social determinants of health and all-cause and cause-specific mortality.

Outcomes HR (95%CI) ACME (95%CI) ADE (95%CI) Total mediation effect (95%CI) Mediation proportion (95%CI)
Unadjusted for CVH Adjusted for CVH
All-cause mortality
Low burden of unfavorable SDoH 1 (Reference) 1 (Reference) 0.004

(0.003-0.005)
0.018

(0.016-0.022)
0.021

(0.020-0.026)
16.70

(10.90-18.96)
High burden of unfavorable SDoH 2.32 (2.04-2.63) 2.14 (1.88-2.44)
CVD mortality
Low burden of unfavorable SDoH 1 (Reference) 1 (Reference) 0.001

(0-0.002)
0.005

(0.004-0.006)
0.006

(0.005-0.007)
22.22

(8.63-27.98)
High burden of unfavorable SDoH 2.21 (1.75-2.80) 2.05 (1.60-2.63)
Cancer mortality
Low burden of unfavorable SDoH 1 (Reference) 1 (Reference) 0.001

(0-0.002)
0.004

(0.002-0.005)
0.005

(0.003-0.006)
17.70

(9.48-42.79)
High burden of unfavorable SDoH 1.72 (1.34-2.22) 1.62 (1.26-2.09)

Multivariate models were adjusted for age, sex, race/ethnicity, cardiovascular disease history, and cancer history.

Abbreviations: SDoH: social determinants of health; CVH: cardiovascular health; HR: hazard ratio; CI: confidence interval; CVD: cardiovascular diseases; ACME: average causal mediation effect; ADE: average direct effect.

Interaction test and combined associations of SDoH and CVH with mortality

A significant additive interaction between SDoH and CVH was observed for all-cause mortality (RERI, 0.42; 95% CI: 0.06–0.78; AP, 0.15; 95% CI: 0.03–0.27; SI, 1.30; 95% CI: 1.02–1.67). Approximately 15% of all-cause mortality risk was attributable to the additive interaction, suggesting the combined effects exceeded the sum of their independent effects. No significant multiplicative interaction was observed (P for interaction>0.05) (Table 4). Stratified by SDoH burden, high CVH attenuated the increased risks of all-cause (HR, 0.43; 95% CI: 0.24–0.75) and CVD (HR, 0.08; 95% CI: 0.01–0.61) mortality associated with a high burden of unfavorable SDoH. Whether in individuals with a high or low burden of unfavorable SDoH, high CVH was both associated with lower risks of all-cause and CVD mortality, whereas the associations were stronger in the high burden group (S3 Fig).

Table 4. Additive and multiplicative interactions of social determinants of health and cardiovascular health for mortality.

Outcomes Additive interaction Multiplicative interaction
RERI (95%CI) AP (95%CI) SI (95%CI) HR (95%CI) P for interaction
All-cause mortality 0.42 (0.06-0.78) 0.15 (0.03-0.27) 1.30 (1.02-1.67) 1.18 (0.91-1.53) 0.223
CVD mortality 0.09 (−0.58-0.76) 0.03 (−0.22-0.29) 1.06 (0.68-1.65) 1.30 (0.85-2.03) 0.091
Cancer mortality 0.60 (0.02-1.19) 0.27 (0.03-0.51) 1.93 (0.84-4.42) 1.20 (0.67-2.14) 0.546

All models were adjusted for age, sex, race/ethnicity, cardiovascular disease history, and cancer history. Additive interaction was evaluated using the RERI, AP, and SI between SDoH and CVH. The RERI and AP were statistically significant when their 95% CIs did not include 0, and the SI was significant when its 95% CI did not include 1. Multiplicative interaction was evaluated using HR for the interaction term between SDoH and CVH, and the multiplicative interaction was statistically significant when its 95% CI did not include 1.

Abbreviations: SDoH: social determinants of health; CVH: cardiovascular health; CI: confidence interval; CVD: cardiovascular diseases; RERI: relative excess risk due to interaction; AP: attributable proportion; SI: synergy index.

Approximately 12.95% of participants exhibited both low CVH and a high burden of unfavorable SDoH, while only 7.81% maintained high CVH with a low burden of unfavorable SDoH (S6 Table). Individuals with low CVH and a high burden of unfavorable SDoH had the highest risks of all-cause, CVD, and cancer mortality. Specifically, compared to individuals with high CVH and a low burden of unfavorable SDoH, the HRs for all-cause, CVD, and cancer mortality in those with low CVH and a high burden of unfavorable SDoH were 4.60 (95% CI: 2.87–7.37), 2.80 (95% CI: 1.10–7.10), and 6.10 (95% CI: 2.13–17.50), respectively (Fig 1).

Fig 1. Combined associations of social determinants of health and cardiovascular health with all-cause and cause-specific mortality.

Fig 1

Participants were classified into six groups according to the combined categories of unfavorable SDoH (low and high burden) and CVH (low, moderate, and high). Multivariate models were adjusted for age, sex, race/ethnicity, cardiovascular disease history, and cancer history. Abbreviations: SDoH: social determinants of health; CVH: cardiovascular health; HR: hazard ratio; CI: confidence interval; CVD: cardiovascular diseases.

Subgroup and sensitivity analyses

Subgroup analyses showed that the combined associations of SDoH and CVH with mortality risks were consistent across age, sex, and racial subgroups (all P for interaction>0.05, S7 Table). Sensitivity analyses yielded consistent results with the primary findings after excluding individuals dead within the first two years of follow-up (S8 Table), those with CVD or cancer history (S9 Table), or further adjusted for CKD, COPD, and drinking status (S10 Table).

Discussion

This study is the first to examine the mediating, interacting, and combined effects of SDoH and CVH on all-cause and cause-specific mortality in a nationally representative sample of U.S. adults. Our findings showed that a high burden of unfavorable SDoH was associated with increased risks of all-cause, CVD, and cancer mortality. Furthermore, CVH mediated 3.92% of the association between SDoH and all-cause mortality. We observed a significant additive interaction between SDoH and CVH for all-cause mortality. Higher CVH levels attenuated the increased all-cause and CVD mortality risks associated with high unfavorable SDoH burden. In combined analyses, individuals with both a high burden of unfavorable SDoH and low CVH exhibited the highest risks of all-cause, CVD, and cancer mortality.

Our findings corroborate established evidence linking adverse SDoH to suboptimal CVH [9]. Socioeconomic advantages, including higher income, educational attainment, occupational status, and social status, are associated with high CVH [9,21,22]. SDoH plays a fundamental role in optimizing CVH, as the various domains of upstream SDoH interact to exert cumulative downstream effects on CVH through complex ways [1,7]. Our results align with the recognized association between adverse SDoH and excess mortality risk [5], with growing evidence indicating that SDoH serve as upstream drivers of the observed mortality disparities [23]. The definitions of SDoH and CVH used in our study are consistent with previous NHANES research [5,13,24], enhancing comparability and reliability of our findings. Although specific definitions of SDoH and CVH may vary across studies due to data availability, consistent evidence indicates that worse SDoH are related to worse CVH, and both are significant mortality risk factors [25,26]. While the complex relationship between SDoH and CVH on mortality remains unclear. Following adjustment for CVH, we observed an attenuation in the association between SDoH and mortality, suggesting a potential mediating role of CVH. Formal mediation analysis confirmed that CVH serves as a statistically significant but modest mediator in the pathways linking SDoH to both all-cause and cause-specific mortality. Nevertheless, the limited magnitude of mediation indicates that substantial reductions of adverse SDoH could not be achieved through promoting CVH alone, and other measures to tackle SDoH are still needed.

Moreover, we observed a significant additive interaction between SDoH and CVH on all-cause mortality. Approximately one-eighth of the excess mortality risk observed in individuals with both low CVH and high SDoH burden was attributable to synergistic effects. This suggests public health interventions simultaneously addressing both risk factors might yield greater mortality risk reduction than targeting either alone. Physiologically, adverse SDoH (e.g., poverty and limited healthcare access) may induce chronic physiological stress, such as dysregulated HPA axis and increased inflammation [7], which increases the adverse effects of low CVH. Resource constraints inherent to unfavorable SDoH concurrently limit the ability to promote CVH behaviors, such as accessing healthy food, safe environments for physical activity, and preventive care [10,23], thus creating a vicious cycle that accelerates health decline. However, the result of our study differs from a Chinese cohort study reporting no interaction between CVH and SDoH [27]. This discrepancy may result from differences in SDoH and CVH definitions, as they used only 5 SDoH sub-items and did not use LE8 to assess CVH. Furthermore, it is noteworthy that high CVH provided greater protection against all-cause and CVD mortality in individuals facing SDoH disadvantages, suggesting the probability of optimizing CVH to mitigate mortality disparities exacerbated by adverse SDoH.

The current study provides novel findings regarding the combined impacts of SDoH and CVH on mortality risks in U.S. adults. Our findings align with the Chinese cohort study in community-dwelling adults without CVD, demonstrating that a high burden of unfavorable SDoH and poor CVH had a combined effect on major adverse cardiovascular events and all-cause mortality [27]. Nationwide cohort studies in the U.K. and the U.S. also reported elevated mortality and CVD risks among individuals with low socioeconomic status (SES) and few healthy lifestyles [15]. While previous research examined combined effects of one or two domains of SDoH and lifestyle components of CVH on clinical outcomes [28,29], our assessment across all SDoH domains and AHA’s standardized LE8 provides a comprehensive evaluation of the combined effects of those two risk factors. This approach enables identification of high-risk subgroups, particularly those experiencing dual burden of adverse SDoH and suboptimal CVH, who face elevated mortality risks. Despite existing evidence of SDoH’s prognostic significance, most mortality prediction frameworks often overlook the contribution of SDoH in risk assessment [30,31]. Our predictive modeling showed that incorporating SDoH and CVH metrics improved risk stratification and prediction accuracy beyond models without SDoH, probably enabling early identification of vulnerable populations and optimized preventive interventions. Nevertheless, large-scale prospective cohort studies warrant to verify our findings.

Our findings demonstrate an intertwined nature of SDoH and CVH and their combined effects on mortality risks, which have implications for incorporating both SDoH and CVH into clinical practice and public health strategies to mitigate mortality disparities. Clinically, systematic screening for concurrent adverse SDoH and suboptimal CVH should identify high-risk individuals by healthcare providers and clinicians. Targeted interventions can then be deployed through multidisciplinary care teams addressing adverse SDoH while optimizing CVH. Concurrently, public health initiatives must address structural determinants through neighborhood investments, health education programs, and economic policies, which should be with population-level CVH promotion. Furthermore, combined assessments of SDoH and CVH are needed to enhance mortality risk prediction and stratification.

The strengths of the study included a nationally representative sample of U.S. adults and the systematic collection of SDoH and CVH metrics using standardized methods. However, several limitations should be acknowledged. First, causality cannot be inferred because of the observational design. Second, single timepoint assessment precludes examining how changes in SDoH or CVH over time influence mortality risk, which represents an important direction for future cohort studies. Third, residual confounding from unmeasured factors (e.g., genetic predisposition, medication adherence) may still exist. Fourth, behavior components of CVH (diet, physical activity, sleep, smoking) and several SDoH domains relied on self-report, which introduced recall bias, social desirability bias, and misclassification. Lastly, approximately 40% of participants were excluded due to missing data on CVH or SDoH components. Differences between the included and excluded participants may introduce selection bias, potentially limiting the generalizability of our findings. Thus, the results should be cautiously interpreted as representative primarily of U.S. adults with complete data on these measures.

Conclusions

In a nationally representative sample of U.S. adults, the coexistence of a high burden of unfavorable SDoH and low CVH was associated with increased risks of all-cause, CVD, and cancer mortality. These findings provide implications for integrating both SDoH and CVH in clinical practice and public health strategies to improve survival outcomes.

Supporting information

S1 Fig. Flowchart of the study.

(DOCX)

pone.0337286.s001.docx (84.2KB, docx)
S1 Table. Methods for evaluating each single cardiovascular health metric.

(DOCX)

pone.0337286.s002.docx (23.3KB, docx)
S2 Table. Definitions of social determinants of health domains and sub-items.

(DOCX)

pone.0337286.s003.docx (19.9KB, docx)
S3 Table. Baseline characteristics of participants included or excluded from the current analysis.

(DOCX)

pone.0337286.s004.docx (20.8KB, docx)
S4 Table. Association between social determinants of health and cardiovascular health.

(DOCX)

pone.0337286.s005.docx (22.2KB, docx)
S2 Fig. Mediation effects of cardiovascular health on the association of social determinants of health with mortality.

(DOCX)

pone.0337286.s006.docx (103.8KB, docx)
S5 Table. Predictive value of models without and with the social determinants of health.

(DOCX)

pone.0337286.s007.docx (19.1KB, docx)
S3 Fig. Association of cardiovascular health with all-cause and cause-specific mortality stratified by levels of social determinants of health.

(DOCX)

pone.0337286.s008.docx (248KB, docx)
S6 Table. Characteristics of participants by combined categories of social determinants of health and cardiovascular health.

(DOCX)

pone.0337286.s009.docx (23.2KB, docx)
S7 Table. Combined association of social determinants of health and cardiovascular health with all-cause and cause-specific mortality among US adults: subgroup analysis.

(DOCX)

pone.0337286.s010.docx (19.1KB, docx)
S8 Table. Combined associations of social determinants of health and cardiovascular health with all-cause and cause-specific mortality among US adults after excluding participants died within 2 years of follow-up: sensitivity analysis.

(DOCX)

pone.0337286.s011.docx (20.5KB, docx)
S9 Table. Combined associations of social determinants of health and cardiovascular health with all-cause and cause-specific mortality among US adults after excluding participants with cardiovascular diseases or cancer: sensitivity analysis.

(DOCX)

pone.0337286.s012.docx (21.8KB, docx)
S10 Table. Combined associations of social determinants of health and cardiovascular health with all-cause and cause-specific mortality among US adults adjusted for more covariates: sensitivity analysis.

(DOCX)

pone.0337286.s013.docx (21.8KB, docx)

Acknowledgments

The authors thank the investigators and participants of the NAHNES study.

Data Availability

Data availability statement The datasets generated and analyzed in this study are available in the NHANES website, https://wwwn.cdc.gov/nchs/nhanes/.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Powell-Wiley TM, Baumer Y, Baah FO, Baez AS, Farmer N, Mahlobo CT, et al. Social Determinants of Cardiovascular Disease. Circ Res. 2022;130(5):782–99. doi: 10.1161/CIRCRESAHA.121.319811 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Marmot M, Friel S, Bell R, Houweling TAJ, Taylor S, Commission on Social Determinants of Health. Closing the gap in a generation: health equity through action on the social determinants of health. Lancet. 2008;372(9650):1661–9. doi: 10.1016/S0140-6736(08)61690-6 [DOI] [PubMed] [Google Scholar]
  • 3.Gómez CA, Kleinman DV, Pronk N, Wrenn Gordon GL, Ochiai E, Blakey C, et al. Addressing Health Equity and Social Determinants of Health Through Healthy People 2030. J Public Health Manag Pract. 2021;27(Suppl 6):S249–57. doi: 10.1097/PHH.0000000000001297 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Liang J-H, Liu M-L, Pu Y-Q, Wang C, Huang S, Jiang N, et al. Contribution of individual and cumulative social determinants of health underlying gender disparities in periodontitis in a representative US population: A cross-sectional NHANES study. J Clin Periodontol. 2024;51(5):558–70. doi: 10.1111/jcpe.13941 [DOI] [PubMed] [Google Scholar]
  • 5.Bundy JD, Mills KT, He H, LaVeist TA, Ferdinand KC, Chen J, et al. Social determinants of health and premature death among adults in the USA from 1999 to 2018: a national cohort study. Lancet Public Health. 2023;8(6):e422–31. doi: 10.1016/S2468-2667(23)00081-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Shah NS, Huang X, Petito LC, Bancks MP, Ning H, Cameron NA, et al. Social and Psychosocial Determinants of Racial and Ethnic Differences in Cardiovascular Health in the United States Population. Circulation. 2023;147(3):190–200. doi: 10.1161/CIRCULATIONAHA.122.061991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Teshale AB, Htun HL, Owen A, Gasevic D, Phyo AZZ, Fancourt D, et al. The Role of Social Determinants of Health in Cardiovascular Diseases: An Umbrella Review. J Am Heart Assoc. 2023;12(13):e029765. doi: 10.1161/JAHA.123.029765 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Organization WH. Social Determinants of Health. 2023. Available from https://www.who.int/health-topics/social-determinants-of-health [Google Scholar]
  • 9.Caleyachetty R, Echouffo-Tcheugui JB, Muennig P, Zhu W, Muntner P, Shimbo D. Association between cumulative social risk and ideal cardiovascular health in US adults: NHANES 1999-2006. Int J Cardiol. 2015;191:296–300. doi: 10.1016/j.ijcard.2015.05.007 [DOI] [PubMed] [Google Scholar]
  • 10.Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, et al. Social Determinants of Risk and Outcomes for Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2015;132(9):873–98. doi: 10.1161/CIR.0000000000000228 [DOI] [PubMed] [Google Scholar]
  • 11.Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121(4):586–613. doi: 10.1161/CIRCULATIONAHA.109.192703 [DOI] [PubMed] [Google Scholar]
  • 12.Lloyd-Jones DM, Allen NB, Anderson CAM, Black T, Brewer LC, Foraker RE, et al. Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. Circulation. 2022;146(5):e18–43. doi: 10.1161/CIR.0000000000001078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ma H, Wang X, Xue Q, Li X, Liang Z, Heianza Y, et al. Cardiovascular Health and Life Expectancy Among Adults in the United States. Circulation. 2023;147(15):1137–46. doi: 10.1161/CIRCULATIONAHA.122.062457 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sun J, Li Y, Zhao M, Yu X, Zhang C, Magnussen CG, et al. Association of the American Heart Association’s new “Life’s Essential 8” with all-cause and cardiovascular disease-specific mortality: prospective cohort study. BMC Med. 2023;21(1):116. doi: 10.1186/s12916-023-02824-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Zhang Y-B, Chen C, Pan X-F, Guo J, Li Y, Franco OH, et al. Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: two prospective cohort studies. BMJ. 2021;373:n604. doi: 10.1136/bmj.n604 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Puka K, Buckley C, Mulia N, Lasserre AM, Rehm J, Probst C. Educational Attainment and Lifestyle Risk Factors Associated With All-Cause Mortality in the US. JAMA Health Forum. 2022;3(4):e220401. doi: 10.1001/jamahealthforum.2022.0401 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Guo C, Liu Z, Fan H, Wang H, Zhang X, Fan C, et al. Associations of healthy lifestyle and three latent socioeconomic status patterns with physical multimorbidity among middle-aged and older adults in China. Prev Med. 2023;175:107693. doi: 10.1016/j.ypmed.2023.107693 [DOI] [PubMed] [Google Scholar]
  • 18.Krebs-Smith SM, Pannucci TE, Subar AF, Kirkpatrick SI, Lerman JL, Tooze JA, et al. Update of the Healthy Eating Index: HEI-2015. J Acad Nutr Diet. 2018;118(9):1591–602. doi: 10.1016/j.jand.2018.05.021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rhee TG, Lee K, Schensul JJ. Black-White Disparities in Social and Behavioral Determinants of Health Index and Their Associations with Self-rated Health and Functional Limitations in Older Adults. J Gerontol A Biol Sci Med Sci. 2021;76(4):735–40. doi: 10.1093/gerona/glaa264 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Rhee TG, Marottoli RA, Cooney LM Jr, Fortinsky RH. Associations of Social and Behavioral Determinants of Health Index with Self-Rated Health, Functional Limitations, and Health Services Use in Older Adults. J Am Geriatr Soc. 2020;68(8):1731–8. doi: 10.1111/jgs.16429 [DOI] [PubMed] [Google Scholar]
  • 21.Piedra LM, Andrade FCD, Hernandez R, Perreira KM, Gallo LC, González HM, et al. Association of Subjective Social Status With Life’s Simple 7s Cardiovascular Health Index Among Hispanic/Latino People: Results From the HCHS/SOL. J Am Heart Assoc. 2021;10(16):e012704. doi: 10.1161/JAHA.119.012704 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Saiz AM Jr, Aul AM, Malecki KM, Bersch AJ, Bergmans RS, LeCaire TJ, et al. Food insecurity and cardiovascular health: Findings from a statewide population health survey in Wisconsin. Prev Med. 2016;93:1–6. doi: 10.1016/j.ypmed.2016.09.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Brandt EJ, Tobb K, Cambron JC, Ferdinand K, Douglass P, Nguyen PK, et al. Assessing and addressing social determinants of cardiovascular health: JACC State-of-the-Art review. J Am Coll Cardiol. 2023;81(14):1368–85. doi: 10.1016/j.jacc.2023.01.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wang Z, Pu B. Joint effects of depression and social determinants of health on mortality risk among U.S. adults: a cohort study. BMC Psychiatry. 2024;24(1):752. doi: 10.1186/s12888-024-06159-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Satti DI, Chan JSK, Dee EC, Lee YHA, Wai AKC, Dani SS, et al. Associations between social determinants of health and cardiovascular health of U.S. adult cancer survivors. JACC CardioOncol. 2024;6(3):439–50. doi: 10.1016/j.jaccao.2023.07.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Satti DI, Chan JSK, Mszar R, Mehta A, Kwapong YA, Chan RNC, et al. Social determinants of health, cardiovascular health, and mortality in sexual minority individuals in the United States. J Am Coll Cardiol. 2025;85(5):515–25. doi: 10.1016/j.jacc.2024.11.026 [DOI] [PubMed] [Google Scholar]
  • 27.Cai A, Chen C, Wang J, Ou Y, Nie Z, Feng Y. Social Determinants of Health, Cardiovascular Health, and Outcomes in Community-Dwelling Adults Without Cardiovascular Disease. JACC Asia. 2023;4(1):44–54. doi: 10.1016/j.jacasi.2023.09.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Li L, Ouyang F, He J, Qiu D, Luo D, Xiao S. Associations of Socioeconomic Status and Healthy Lifestyle With Incidence of Dyslipidemia: A Prospective Chinese Governmental Employee Cohort Study. Front Public Health. 2022;10:878126. doi: 10.3389/fpubh.2022.878126 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bernini S, Conti S, Perdixi E, Jesuthasan N, Costa A, Severgnini M, et al. Investigating the individual and joint effects of socioeconomic status and lifestyle factors on mild cognitive impairment in older Italians living independently in the community: results from the NutBrain study. J Nutr Health Aging. 2024;28(3):100040. doi: 10.1016/j.jnha.2024.100040 [DOI] [PubMed] [Google Scholar]
  • 30.Hammond G, Johnston K, Huang K, Joynt Maddox KE. Social Determinants of Health Improve Predictive Accuracy of Clinical Risk Models for Cardiovascular Hospitalization, Annual Cost, and Death. Circ Cardiovasc Qual Outcomes. 2020;13(6):e006752. doi: 10.1161/CIRCOUTCOMES.120.006752 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Tan M, Hatef E, Taghipour D, Vyas K, Kharrazi H, Gottlieb L, et al. Including Social and Behavioral Determinants in Predictive Models: Trends, Challenges, and Opportunities. JMIR Med Inform. 2020;8(9):e18084. doi: 10.2196/18084 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Angela Freitas

7 Aug 2025

Dear Dr. Pu,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Based on the reviewers' comments, there are some methodological concerns that we kindly ask you to address  in specific to enhance the clarity and soundness of your manuscript.

==============================

Please submit your revised manuscript by Sep 21 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Angela Mendes Freitas

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf   and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We noticed you have some minor occurrence of overlapping text with the following previous publication(s), which needs to be addressed:

https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-024-06159-3

https://www.sciencedirect.com/science/article/abs/pii/S0022399924004446?via%3Dihub

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the methods section. Further consideration is dependent on these concerns being addressed.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information .

5. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 

7. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: The text presented analysis the associations of cardiovascular health and social determinants of health with the risks of

all-cause and cause-specific mortality.

The text is very well organized and clearly written. The authors should be commended for their work and I have only suggestions to improve the way the paper communicates its message

Abstract:

The moderation (interaction) and mediation effects should be stated in the method part

Introduction

-the first time CVH is mentioned use the full form

Results

- I suggest the authors to consider other methods to measure mediation or to present measures such as direct effect| average mediated effect | indirect effect

- Similarly, I suggest a visual result scheme synthesis with the pathways proposed. This is more useful to better understand mediated and interaction analysis

Discussion

- The interpretation of the pathways could be better explained. For instance, "The interaction between SDoH and CVH on mortality was evaluated, revealing a significant additive interaction between these factors on all-cause mortality. Approximately one-eighth of all-cause mortality in individuals with low CVH and a high burden of unfavorable SDoH were attributed to the combined effects of these two risk factors"

But the authors do not explain how from the social and/or biological perspective there is an interaction

Reviewer #2: This study evaluates the combined impact of cardiovascular health (CVH), assessed by Life’s Essential 8 (LE8), and unfavorable social determinants of health (SDoH) on mortality risks among 20,096 U.S. adults using NHANES 2007-2018 data. The authors report notably elevated hazards for all-cause and cause-specific mortality in those with low CVH and ≥3 unfavorable SDoH compared to counterparts with high CVH and fewer SDoH issues (HR 4.60, 95% CI 2.87-7.37). The topic is highly relevant, and the dataset is robust. Here are my few comments and suggestions:

• Only 3.9% of the SDoH-mortality relationship is mediated by LE8, yet the manuscript strongly emphasizes CVH as a crucial mediator. Clearly address and contextualize this minor mediating role. Consider discussing other potential pathways or confounding factors explaining the observed associations.

• One of the major things that bothered me were missing covariates such as chronic kidney dx, lung dx, alcohol consumption, smoking, etc. I believe this could result in substantial residual confounding. I would suggest authors to perform additional analyses by including these important covariates.

• The manuscript used cause-specific cox models, treating deaths from other causes as censored observations. It would be better to do a competing risk analysis such as Fine-Gray competing risk to validate the robustness of the findings.

• Although understandable, many LE8 components such as diet, physical activity, sleep, smoking relied on self report single time assessments. I would encourage authors to highlight this database limitation and acknowledge the measurement bias that could have led to potential misclassification

• The authors excluded around 40% of NHANES respondents due to missing LE8 or SDoH data. I would like to see a more thorough comparison between included and excluded subjects and would encourage the authors to discuss implications for generalizability explicitly.

• The authors should discuss how their SDoH score compares with the scores used in previous SDoH and CVH studies:

o Satti DI, Chan JSK, Mszar R, Mehta A, Kwapong YA, Chan RNC, Agboola O, Spatz ES, Spitz JA, Nasir K, Javed Z, Bonomo JA, Sharma G. Social Determinants of Health, Cardiovascular Health, and Mortality in Sexual Minority Individuals in the United States. J Am Coll Cardiol. 2025 Feb 11;85(5):515-525. doi: 10.1016/j.jacc.2024.11.026. PMID: 39909683.

o Satti DI, Chan JSK, Dee EC, Lee YHA, Wai AKC, Dani SS, Virani SS, Shapiro MD, Sharma G, Liu T, Tse G. Associations Between Social Determinants of Health and Cardiovascular Health of U.S. Adult Cancer Survivors. JACC CardioOncol. 2023 Oct 24;6(3):439-450. doi: 10.1016/j.jaccao.2023.07.010. PMID: 38983373; PMCID: PMC11229543.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org

PLoS One. 2025 Nov 24;20(11):e0337286. doi: 10.1371/journal.pone.0337286.r002

Author response to Decision Letter 1


20 Sep 2025

Submission ID: PONE-D-25-13601

Associations of cardiovascular health and social determinants of health with the risks of all-cause and cause-specific mortality

Response to Comments

Thank you for inviting us to submit a revision of the manuscript for consideration for publication in PLOS One. We appreciate the editor and reviewers’ thoughtful comments, which have helped us to improve our submission. We have prepared responses and modified the manuscript based on the Editor’s requirements for resubmission and have responded to each comment. Specifically, herein we:

• Provide a point-by-point response to the reviewers' comments; the modified text, page numbers, paragraphs, and line numbers are provided.

• Itemize changes that have been made in the manuscript in response to comments by the reviewers.

• Provide two copies of the revision, one in which the changes made are highlighted and a clean second copy.

Reviewer Comments:

For Reviewer 1:

Reviewer #1: The text presented analysis the associations of cardiovascular health and social determinants of health with the risks of all-cause and cause-specific mortality.

The text is very well organized and clearly written. The authors should be commended for their work and I have only suggestions to improve the way the paper communicates its message

1. Abstract:

The moderation (interaction) and mediation effects should be stated in the method part

Response: Thanks for your suggestion. We have added the methods of mediation analysis and interaction analysis into the methods section of the abstract.

After revision:

Abstract (page 2, paragraph 2, lines 28-29): Mediation analysis was used to analyze the mediating role of CVH between SDoH and mortality. Interaction effects were tested by adding interaction terms between CVH and SDoH in the Cox models.

2. Introduction

-the first time CVH is mentioned use the full form

Response: Thank you for your reminder. We have already used the full name "cardiovascular health" (CVH) at the first occurrence in the main text of CVH, and subsequently, the abbreviation "CVH" is used in the rest of the main text.

3. Results

- I suggest the authors to consider other methods to measure mediation or to present measures such as direct effect| average mediated effect | indirect effect

- Similarly, I suggest a visual result scheme synthesis with the pathways proposed. This is more useful to better understand mediated and interaction analysis

Response: Thanks for your comments. We performed mediation analyses using the R package “mediation” to assess the extent to which CVH mediates the association between SDoH and mortality. We have now accounted for the complex survey design of NHANES by incorporating sampling weights through the R “survey” package prior to conducting mediation analysis. The “mediate” function was then applied using 1000 bootstrap simulations to ensure robust estimation of effect sizes and 95% confidence intervals. Accordingly, we have updated the description of the mediation analysis in the Methods section. The Results section and Table 3 have also been revised to present the updated mediation results, including the indirect (average causal mediation effect [ACME]), direct (average direct effect [ADE]), and total effects (ACME+ADE), as well as mediation proportions. Additionally, as suggested, we have added S2 Figure in the Supporting information to visually illustrate the mediation pathways and effect estimates.

After revision:

Methods (page 7, paragraph 4, lines 154-159): Mediation analyses were conducted using the R package "mediation" to quantify the extent to which CVH mediates the association between SDoH and mortality, with the proportion of mediation quantified by comparing models with and without adjustment for CVH. Bootstrap resampling (1000 simulations) was used to estimate of the mediation effect and its 95% confidence interval (95% CIs).

Results (page 9, paragraph 3, lines 212-218): When additionally adjusting for CVH, the HRs for the association between SDoH and all-cause, CVD, and cancer mortality were attenuated but still significant compared with models without CVH adjustment. Mediation analyses further showed that CVH significantly mediated the association between SDoH and all-cause mortality (mediation proportion: 16.70%; 95% CI: 10.90-18.96), CVD mortality (22.22%; 95% CI: 8.63-27.98), and cancer mortality (17.70%; 95% CI: 9.48-42.79) (Table 3, S2 Figure).

4.Discussion

The interpretation of the pathways could be better explained. For instance, "The interaction between SDoH and CVH on mortality was evaluated, revealing a significant additive interaction between these factors on all-cause mortality. Approximately one-eighth of all-cause mortality in individuals with low CVH and a high burden of unfavorable SDoH were attributed to the combined effects of these two risk factors" But the authors do not explain how from the social and/or biological perspective there is an interaction.

Response: Thank you for this insightful suggestion. We have revised the Discussion section to propose potential mechanisms of the interaction effect.

After revision:

Discussion (page 12, paragraph 2, lines 284-301): Moreover, we observed a significant additive interaction between SDoH and CVH on all-cause mortality. Approximately one-eighth of the excess mortality risk observed in individuals with both low CVH and high SDoH burden was attributable to synergistic effects. This suggests public health interventions simultaneously addressing both risk factors might yield greater mortality risk reduction than targeting either alone. Physiologically, adverse SDoH (e.g., poverty and limited healthcare access) may induce chronic physiological stress, such as dysregulated HPA axis and increased inflammation,7 which increases the adverse effects of low CVH. Resource constraints inherent to unfavorable SDoH concurrently limit the ability to promote CVH behaviors, such as accessing healthy food, safe environments for physical activity, and preventive care,10,23 thus creating a vicious cycle that accelerates health decline. However, the result of our study differs from a Chinese cohort study reporting no interaction between CVH and SDoH.27 This discrepancy may result from differences in SDoH and CVH definitions, as they used only 5 SDoH sub-items and did not use LE8 to assess CVH.27 Furthermore, it is noteworthy that high CVH provided greater protection against all-cause and CVD mortality in individuals facing SDoH disadvantages, suggesting the probability of optimizing CVH to mitigate mortality disparities exacerbated by adverse SDoH.

For Reviewer 2:

Reviewer #2: This study evaluates the combined impact of cardiovascular health (CVH), assessed by Life’s Essential 8 (LE8), and unfavorable social determinants of health (SDoH) on mortality risks among 20,096 U.S. adults using NHANES 2007-2018 data. The authors report notably elevated hazards for all-cause and cause-specific mortality in those with low CVH and ≥3 unfavorable SDoH compared to counterparts with high CVH and fewer SDoH issues (HR 4.60, 95% CI 2.87-7.37). The topic is highly relevant, and the dataset is robust. Here are my few comments and suggestions:

1. Only 3.9% of the SDoH-mortality relationship is mediated by LE8, yet the manuscript strongly emphasizes CVH as a crucial mediator. Clearly address and contextualize this minor mediating role. Consider discussing other potential pathways or confounding factors explaining the observed associations.

Response: Thanks for your comments. Our initial mediation analysis did not account for the complex survey design of NHANES. In this revision, we have re-conducted the analysis incorporating sampling weights and now report that CVH served as a significant mediator in the associations between SDoH and all-cause, cardiovascular, and cancer mortality, albeit with relatively modest mediation proportions. We agree that the magnitude of mediation is limited and have revised the manuscript accordingly to update these findings. In the Results section (Page 9, Line 214-218), we now state: "Mediation analyses further showed that CVH significantly mediated the association between SDoH and all-cause mortality (mediation proportion: 16.70%; 95% CI: 10.90-18.96), CVD mortality (22.22%; 95% CI: 8.63-27.98), and cancer mortality (17.70%; 95% CI: 9.48-42.79) (Table 3, S2 Figure)." to accurately show the magnitude.

Moreover, we have expanded the Discussion (Page 11, Lines 276-183) to discuss the modest mediating role: "Following adjustment for CVH, we observed an attenuation in the association between SDoH and mortality, suggesting a potential mediating role of CVH. Formal mediation analysis confirmed that CVH serves as a statistically significant but modest mediator in the pathways linking SDoH to both all-cause and cause-specific mortality. Nevertheless, the limited magnitude of mediation indicates that substantial reductions of adverse SDoH could not be achieved through promoting CVH alone, and other measures to tackle SDoH are still needed."

2. One of the major things that bothered me were missing covariates such as chronic kidney dx, lung dx, alcohol consumption, smoking, etc. I believe this could result in substantial residual confounding. I would suggest authors to perform additional analyses by including these important covariates.

Response: Thanks for your suggestions. 1. Smoking: as smoking status is a core component of CVH (health behavior domain), adjusting for it again das a separate covariate would constitute over-adjustment. Therefore, we did not include it as an additional covariate. 2. We agree these are potential confounders not originally adjusted for. We have now performed a sensitivity analysis further adjusting for additional covariates including drinking status, chronic kidney disease (CKD), and chronic obstructive pulmonary disease (COPD). Drinking status was classi�ed as current drinkers or noncurrent-drinkers. CKD was defined as meeting one of the following: estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 or urinary albumin-to-creatinine ratio (ACR)≥ 30 mg/g. COPD was self-reported history of COPD. The result of this sensitivity analysis is shown in S10 Table of the supporting information, which is consistent with the primary results.

3. The manuscript used cause-specific cox models, treating deaths from other causes as censored observations. It would be better to do a competing risk analysis such as Fine-Gray competing risk to validate the robustness of the findings.

Response: This is a good question. We acknowledge the theoretical advantage of competing risk models like Fine-Gray for cause-specific mortality. However, standard statistical software (e.g., R packages survey, cmprsk, tidycmprsk) currently lacks methods for incorporating NHANES sampling weights into Fine-Gray models. Using an unweighted Fine-Gray model might underestimate the nationally representative nature of our estimates. Therefore, to maintain the integrity of the population-representative analysis, we used the standard approach for cause-specific mortality in complex surveys: weighted Cox proportional hazards models treating deaths from other causes as censoring events. To address your concern about robustness, we performed unweighted Fine-Gray competing risk analyses of CVD mortality and cancer mortality (seen below). The results of CVD and cancer mortality were consistent with our primary weighted Cox models.

Outcomes CVH Hazard ratio (95% confidence interval)

CVD mortality

High burden of unfavorable SDoH High 1 (Reference)

Moderate 0.87 (0.49-2.32)

Low 1.62 (0.73-3.61)

Low burden of unfavorable SDoH High 0.34 (0.04-2.78)

Moderate 1.98 (0.92-4.26)

Low 2.38 (1.10-5.14)

Cancer mortality

High burden of unfavorable SDoH High 1 (Reference)

Moderate 1.95 (0.81-4.69)

Low 2.25 (0.91-5.57)

Low burden of unfavorable SDoH High 2.74 (0.85-8.87)

Moderate 2.46 (1.02-5.91)

Low 3.77 (1.56-9.08)

4. Although understandable, many LE8 components such as diet, physical activity, sleep, smoking relied on self-report single time assessments. I would encourage authors to highlight this database limitation and acknowledge the measurement bias that could have led to potential misclassification.

Response: We fully agree with the comment and have strengthened the acknowledgment of this limitation in the Discussion section (Page 13, Lines 334-346): "However, several limitations should be acknowledged. First, causality cannot be inferred because of the observational design. Second, single timepoint assessment precludes examining how changes in SDoH or CVH over time influence mortality risk, which represents an important direction for future cohort studies. Third, residual confounding from unmeasured factors (e.g., genetic predisposition, medication adherence) may still exist. Fourth, behavior components of CVH (diet, physical activity, sleep, smoking) and several SDoH domains relied on self-report, which introduced recall bias, social desirability bias, and misclassification. Lastly, approximately 40% of participants were excluded due to missing data on CVH or SDoH components. Differences between the included and excluded participants may introduce selection bias, potentially limiting the generalizability of our findings. Thus, the results should be cautiously interpreted as representative primarily of U.S. adults with complete data on these measures."

5. The authors excluded around 40% of NHANES respondents due to missing LE8 or SDoH data. I would like to see a more thorough comparison between included and excluded subjects and would encourage the authors to discuss implications for generalizability explicitly.

Response: Thanks for your comment. As shown in Figure S1 of the supporting information, the NHANES 2007-2018 database included a total of 59,842 participants. We first excluded 25,072 participants <20 years, 372 pregnant women, and 115 with missing values of mortality data. Then, we excluded 14,187 participants who lacked data on CVH or SDoH. Finally, we included 20,096 participants for analysis. Therefore, the proportion of participants with missing CVH or SDoH data was 35.7% of the total excluded participants. According to your suggestion, we added more characteristics in S3 Table of the supporting information to compare the baseline characteristics of participants included or excluded from our analysis. We found that excluded participants were younger, had a lower prevalence of CVD and cancer, and had more unfavorable SDoH than included participants; however, their CVH was comparable.

In addition, we have revised this limitation in the discussion "approximately 40% of participants were excluded due to missing data on CVH or SDoH components. Differences between the included and excluded participants may introduce selection bias, potentially limiting the generalizability of our findings. Thus, the results should be cautiously interpreted as representative primarily of U.S. adults with complete data on these measures.”

6. The authors should discuss how their SDoH score compares with the scores used in previous SDoH and CVH studies:

o Satti DI, Chan JSK, Mszar R, Mehta A, Kwapong YA, Chan RNC, Agboola O, Spatz ES, Spitz JA, Nasir K, Javed Z, Bonomo JA, Sharma G. Social Determinants of Health, Cardiovascular Health, and Mortality in Sexual Minority Individuals in the United States. J Am Coll Cardiol. 2025 Feb 11;85(5):515-525. doi: 10.1016/j.jacc.2024.11.026. PMID: 39909683.

o Satti DI, Chan JSK, Dee EC, Lee YHA, Wai AKC, Dani SS, Virani SS, Shapiro MD, Sharma G, Liu T, Tse G. Associations Between Social Determinants of Health and Cardiovascular Health of U.S. Adult Cancer Survivors. JACC CardioOncol. 2023 Oct 24;6(3):439-450. doi: 10.1016/j.jaccao.2023.07.010. PMID: 38983373; PMCID: PMC11229543.

Response: Thanks for your suggestion. We carefully read these two articles you mentioned. The two articles were both based on the same database "National Health Interview Survey (NHIS)", and were written by the same author team. Due to the limitation of the availability of NHIS survey data from the U.S., they used 6 domains to define SDoH; while we used 5 domains to define SDoH, compared with their domains, we lacked the "community and s

Attachment

Submitted filename: Point by point response to reviewers.docx

pone.0337286.s015.docx (38.7KB, docx)

Decision Letter 1

Angela Freitas

7 Nov 2025

Associations of cardiovascular health and social determinants of health with the risks of all-cause and cause-specific mortality

PONE-D-25-13601R1

Dear Dr. Pu,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support .

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Angela Mendes Freitas

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

**********

Reviewer #1: The authors addressed all questions raised. I consider the text has the quality needed for publishing.

Reviewer #2: The manuscript has improved significantly and I commend the authorship team for making all the changes. I have no further comments.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

Acceptance letter

Angela Freitas

PONE-D-25-13601R1

PLOS ONE

Dear Dr. Pu,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Angela Mendes Freitas

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Flowchart of the study.

    (DOCX)

    pone.0337286.s001.docx (84.2KB, docx)
    S1 Table. Methods for evaluating each single cardiovascular health metric.

    (DOCX)

    pone.0337286.s002.docx (23.3KB, docx)
    S2 Table. Definitions of social determinants of health domains and sub-items.

    (DOCX)

    pone.0337286.s003.docx (19.9KB, docx)
    S3 Table. Baseline characteristics of participants included or excluded from the current analysis.

    (DOCX)

    pone.0337286.s004.docx (20.8KB, docx)
    S4 Table. Association between social determinants of health and cardiovascular health.

    (DOCX)

    pone.0337286.s005.docx (22.2KB, docx)
    S2 Fig. Mediation effects of cardiovascular health on the association of social determinants of health with mortality.

    (DOCX)

    pone.0337286.s006.docx (103.8KB, docx)
    S5 Table. Predictive value of models without and with the social determinants of health.

    (DOCX)

    pone.0337286.s007.docx (19.1KB, docx)
    S3 Fig. Association of cardiovascular health with all-cause and cause-specific mortality stratified by levels of social determinants of health.

    (DOCX)

    pone.0337286.s008.docx (248KB, docx)
    S6 Table. Characteristics of participants by combined categories of social determinants of health and cardiovascular health.

    (DOCX)

    pone.0337286.s009.docx (23.2KB, docx)
    S7 Table. Combined association of social determinants of health and cardiovascular health with all-cause and cause-specific mortality among US adults: subgroup analysis.

    (DOCX)

    pone.0337286.s010.docx (19.1KB, docx)
    S8 Table. Combined associations of social determinants of health and cardiovascular health with all-cause and cause-specific mortality among US adults after excluding participants died within 2 years of follow-up: sensitivity analysis.

    (DOCX)

    pone.0337286.s011.docx (20.5KB, docx)
    S9 Table. Combined associations of social determinants of health and cardiovascular health with all-cause and cause-specific mortality among US adults after excluding participants with cardiovascular diseases or cancer: sensitivity analysis.

    (DOCX)

    pone.0337286.s012.docx (21.8KB, docx)
    S10 Table. Combined associations of social determinants of health and cardiovascular health with all-cause and cause-specific mortality among US adults adjusted for more covariates: sensitivity analysis.

    (DOCX)

    pone.0337286.s013.docx (21.8KB, docx)
    Attachment

    Submitted filename: Point by point response to reviewers.docx

    pone.0337286.s015.docx (38.7KB, docx)

    Data Availability Statement

    Data availability statement The datasets generated and analyzed in this study are available in the NHANES website, https://wwwn.cdc.gov/nchs/nhanes/.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES